Pantoprazole Viatris (Pantoprazole Sodium Sesquihydrate)

Pantoprazole blocks the H+/K+‑ATPase enzyme, also known as the gastric proton pump, on the surface of parietal cells. This inhibition stops the final step of acid production, leading to a sustained increase in gastric pH and decreased acidity in the stomach.

The specific dose of Pantoprazole Viatris is determined by the prescribing clinician based on the patient’s condition, severity and response to therapy. Dosage forms and strengths are selected to match the therapeutic need, and patients should follow the prescriber’s instructions.

Pantoprazole is classified as pregnancy category B in many regions, indicating no evidence of risk in animal studies but limited human data. It should be used only if clearly needed after a risk‑benefit assessment. Limited amounts are excreted in breast milk; breastfeeding mothers should consult their healthcare provider.

To request Pantoprazole Viatris, visit the product page on gnhindia.com, enter the required quantity and submit the enquiry form. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Pantoprazole shares the same class mechanism as other PPIs such as omeprazole and esomeprazole, providing potent acid suppression. Compared with some alternatives, pantoprazole has a lower potential for drug‑drug interactions involving CYP2C19 metabolism, making it a preferred option for patients on multiple medications.

Pantoprazole Viatris tablets should be stored at temperatures below 25 °C, in the original packaging to protect from moisture and light. Keeping the product in a dry, cool environment helps maintain its potency throughout its shelf life.

Pantoprazole Viatris is supplied as oral tablets that are swallowed whole with water. It is usually taken before a meal, often in the morning, but patients should follow the specific timing advised by their prescriber.

Serious risks, though uncommon, include severe allergic reactions (anaphylaxis), Clostridioides difficile‑associated colitis, low magnesium levels, and increased risk of bone fractures with long‑term therapy. Patients should seek immediate medical attention if they experience symptoms such as rash, persistent diarrhoea, muscle cramps or unexplained fractures.

Individuals with a known hypersensitivity to pantoprazole, other proton pump inhibitors, or any component of the formulation should avoid the product. Caution is also advised for patients with severe liver impairment, and it is contraindicated in those with a documented allergy to the drug.